Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 236,452,287 papers from all fields of science
Search
Sign In
Create Free Account
lumiliximab
Known as:
p5E8
, monoclonal antibody lumiliximab
, anti-CD23 Antibody
Expand
IDEC-152 was developed to decrease the body's response to allergens, thereby affecting diseases related to asthma and allergic disorders. This…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
IDEC-152
antigen binding
cyclophosphamide/fludarabine/lumiliximab/rituximab
Broader (1)
Monoclonal Antibodies
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
USE OF CD 23 ANTIBODIES TO TREAT MALIGNANCIES
2017
Corpus ID: 59477867
The invention relates to methods of treating B-cell chronic lymphocytic leukemia, and other CD23 malignancies, in patients with…
Expand
2013
2013
lymphocytic leukemia cells and CD23+ lymphoma cell lines Mediation of apoptosis by and anti-tumor activity of lumiliximab in chronic
N. Pathan
,
P. Chu
,
K. Hariharan
,
C. Cheney
,
A. Molina
,
J. Byrd
2013
Corpus ID: 82028461
Abstract Lumiliximab is a chimeric macaque-human monoclonal antibody to CD23, a protein expressed on virtually all chronic…
Expand
2008
2008
Correlation of clinical activity of lumiliximab in combination with FCR and ZAP 70 expression on B-cell chronic lymphocytic leukemia cells
N. Pathan
,
Annalee Estrellado
,
+6 authors
S. Tangri
2008
Corpus ID: 74229106
7073 Background: Lumiliximab is an anti-CD23 monoclonal antibody under investigation for the treatment of patients with relapsed…
Expand
2008
2008
"Not only presidential candidates from Illinois" Haematology news from ASCO 2008
W. Willenbacher
2008
Corpus ID: 71691701
SummaryAt the haematological sessions of ASCO 2008 major progress was reported with regard to multiple aspects of haematologic…
Expand
2008
2008
Gateways to clinical trials.
A. Tomillero
,
M. A. Moral
Methods and Findings in Experimental and Clinical…
2008
Corpus ID: 26153196
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the…
Expand
2007
2007
Lumiliximab (anti-CD23 antibody) mediates apoptosis and antitumor activity in chronic lymphocytic leukemia (CLL) cells and CD23+ lymphoma cell lines
N. Pathan
,
J. Byrd
,
K. Hariharan
,
P. Chu
,
A. Molina
2007
Corpus ID: 86190138
3039 Background: Given the success of treating CLL with antibody therapies, interest in those directed at alternative B-cell…
Expand
2007
2007
Phase 1 Study of Lumiliximabwith Detailed Pharmacokinetic and PharmacodynamicMeasurements in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
J. Byrd
,
S. O'brien
,
+10 authors
S. Harris
2007
Corpus ID: 15303564
Purpose:Therapeutic antibodies have improved the outcome for patientswith chronic lymphocytic leukemia (CLL).We conducted a…
Expand
2007
2007
Lumiliximab shows potential in CLL
2007
Corpus ID: 195118542